• Home
  • EMCrit-RACC
  • PulmCrit
  • IBCC
  • EMNerd
  • Tox & Hound
  • iSepsis
  • About
    • About EMCrit
    • About PulmCrit
    • EMCrit FAQ
    • Subscription Options
  • Contact Us

PulmCrit (EMCrit)

Online Medical Education on Emergency Department (ED) Critical Care, Trauma, and Resuscitation

  • About PulmCrit
  • Genius General Hospital
  • PulmCrit TOC
  • IBCC TOC
  • IBCC Podcast
You are here: Home / PULMCrit / PulmCrit: The surviving sepsis campaign 1-hour bundle is… back?

PulmCrit: The surviving sepsis campaign 1-hour bundle is… back?

February 12, 2019 by Josh Farkas 2 Comments

The surviving sepsis campaign (SSC) has had substantial problems dating back to its inception.  The original backbone of the guidelines was a single-center trial by Rivers, which has largely been debunked.1–4  Initially the SSC was slow to let go of invasive early goal-directed therapy.  The SSC has finally started eliminating older dogma (e.g., superior vena cava oxygen saturation), but it’s merely replacing it with newer dogma (e.g., 30 cc/kg fluid for all).  This is more fashionable, but equally unscientific.

The SSC released a new one-hour bundle last year.5  This was an abrupt departure from all previous guidelines, which have recommended initiating treatment within 3-6 hours.6–9  The change was largely arbitrary, without new high-quality evidence to support it (indeed, all of these time cutoffs are arbitrary).  Based on the epic failure of the 4-hour antibiotic rule for pneumonia, a 1-hour sepsis rule would likely lead to hasty management decisions and shotgun treatment.10–12

The 1-hour SSC bundle was met with considerable resistance.13  A petition to retract the new bundle received over 6,000 signatures.  Whether the surviving sepsis campaign should be retired was openly debated within the CHEST journal and at the ESICM conference:14,15

These debates confirmed our suspicion that there is no high-quality prospective evidence supporting the 1-hour bundle.  We didn’t overlook it; it simply does not exist.  When challenged to support the 1-hour bundle, the SSC referred only to retrospective studies (especially correlational time-to-intervention studies).  Such studies cannot form the basis for international treatment recommendations.  That would be akin to taking a drug from a phase-I clinical trial directly to the market (short-cutting phase-II or phase-III trials).  A one-hour bundle has never been prospectively tested in any hospital, yet SSC wants to initiate it in every hospital.

In response to widely expressed concerns, in September the Society of Critical Care Medicine (SCCM) and the American College of Emergency Physicians (ACEP) issued a joint statement that hospitals should not implement the one-hour bundle pending further review (shown below).  This statement was also endorsed by the American Academy of Emergency Medicine (AAEM).

Let’s take a moment to reflect on how unusual this statement is.  Freshly released treatment recommendations should represent the crème de la crème of cutting edge, evidence-based medicine.  Such statements are usually well received and rapidly incorporated into practice.  The need for the American College of Emergency Physicians to step in and place a hold on implementing this is extremely unusual.

The #SurvivingSepsis Campaign’s Hour-1 Bundle has been updated and is ready for implementation. Access teaching slides, videos, pocket cards, an infographic, and review the 2016 practice guidelines here: https://t.co/LrD1DCzk1U pic.twitter.com/Gt6eVpv51b

— SCCM (@SCCM) January 29, 2019

The SSC updated the 1-hour bundle with minor changes, leaving it nearly indistinguishable from the original version (tweet above).  The SSC has now resumed efforts to promote the 1-hour bundle, in collaboration with the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM).  A spokesperson of the American College of Emergency Physicians (ACEP) commented on these developments as follows:

ACEP is disappointed that concerns about the safety of emergency patients with sepsis or symptoms of sepsis are not being heard by SCCM leadership.  Treatment guidelines for sepsis should not take a one-size-fits-all approach across medical specialties or geographic regions.  We will continue to try to work with SCCM leadership and other experts on practical sepsis treatment guidelines.  Our priority is creating policy that ensures quality care for our patients and provides clear treatment guidelines applicable to emergency care.

Persistent efforts to promote the 1-hour bundle are unwise and inexplicable.  The lack of adequate evidence undergirding the 1-hour bundle has now been clearly exposed.  Thousands of healthcare professionals and two emergency medicine societies have expressed their concern.

For a fair presentation of both sides of this issues, see the full pro/con debate from CHEST freely available right here.  Please read this carefully, with attention to the level of evidence supporting various claims.  Consider also that the burden of proof lies with those writing international treatment recommendations.

Knowledge translation takes decades.  Furthermore, de-adoption is harder than adoption.  Therefore, the SSC will probably continue to myopically lumber forwards for some time.  The arc of intensive care is long, but it bends towards evidence.  For now, caveat emptor:  pay careful attention to available evidence before considering implementation of the 1-hour bundle.

Further reading
  • Marik et al.  Pro-Con debate:  Should the Surviving sepsis campaign guidelines be retired?  CHEST  2019; 155:12-20.
  • Kalantari A and Rezaie SR.  Challenging the one-hour sepsis bundle.  Western Journal of Emergency Medicine, in press.
  • Spiegel R et al.  The 2018 Surviving Sepsis Campaign's Treatment Bundle:  When guidelines outpace the evidence supporting their use.  Annals of Emergency Medicine, 2018.
References
1.
Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368-1377. [PubMed]
2.
ProCESS I, Yealy D, Kellum J, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014;370(18):1683-1693. [PubMed]
3.
ARISE I, ANZICS C, Peake S, et al. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014;371(16):1496-1506. [PubMed]
4.
Mouncey P, Osborn T, Power G, et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2015;372(14):1301-1311. [PubMed]
5.
Levy M, Evans L, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care Med. 2018;44(6):925-928. [PubMed]
6.
Dellinger R, Carlet J, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32(3):858-873. [PubMed]
7.
Dellinger R, Levy M, Carlet J, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008;34(1):17-60. [PubMed]
8.
Dellinger R, Levy M, Rhodes A, et al. Surviving sepsis campaign:  international guidelines for management of severe sepsis and septic shock:  2012. Crit Care Med. 2013;41(2):580-637. [PubMed]
9.
Rhodes A, Evans L, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304-377. [PubMed]
10.
Welker J, Huston M, McCue J. Antibiotic timing and errors in diagnosing pneumonia. Arch Intern Med. 2008;168(4):351-356. [PubMed]
11.
Kanwar M, Brar N, Khatib R, Fakih M. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest. 2007;131(6):1865-1869. [PubMed]
12.
Polgreen P, Chen Y, Cavanaugh J, et al. An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. Infect Control Hosp Epidemiol. 2007;28(2):212-214. [PubMed]
13.
Spiegel R, Farkas J, Rola P, et al. The 2018 Surviving Sepsis Campaign’s Treatment Bundle: When Guidelines Outpace the Evidence Supporting Their Use. Ann Emerg Med. August 2018. [PubMed]
14.
Marik P, Farkas J, Spiegel R, Weingart S, collaborating authors. POINT: Should the Surviving Sepsis Campaign Guidelines Be Retired? Yes. Chest. 2019;155(1):12-14. [PubMed]
15.
Marik P, Farkas J, Spiegel R, Weingart S, collaborating authors. Rebuttal From Drs Marik, Farkas, Spiegel et al. Chest. 2019;155(1):17-18. [PubMed]
  • About
  • Latest Posts
Josh Farkas
Social Me

Josh Farkas

Josh is the creator of PulmCrit.org. He is an assistant professor of Pulmonary and Critical Care Medicine at the University of Vermont (Burlington Vermont, USA).
Josh Farkas
Social Me

Latest posts by Josh Farkas (see all)

  • IBCC chapter & cast:Hypernatremia - February 21, 2019
  • PulmCrit:Is pure RSI a failed paradigm in critical illness?The primacy of pressure - February 19, 2019
  • IBCC chapter:Salicylate intoxication - February 14, 2019

Share this:

  • Facebook
  • Twitter
  • Reddit
  • Pinterest
  • Email
  • Print

Filed Under: PULMCrit


2
Comment Here

avatar
Role
1 Comment threads
1 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
2 Comment authors
Josh FarkasNATHAN MCNEIL Recent comment authors
avatar
Role
newest oldest most voted
NATHAN MCNEIL
Guest
NATHAN MCNEIL

Who funds the surviving sepsis campaign?

What's Your Job?
ED doc
Vote Up0Vote Down  Reply
10 days ago
Josh Farkas
Author
Josh Farkas

Have wondered the same. Also: in what other situation does a stand-alone organization write guidelines?

What's Your Job?
intensivist
Vote Up0Vote Down  Reply
10 days ago

Follow EMCrit Everywhere

Click for More Subscribe Options


Other Stuff

  • Have a great idea for the next podcast? Share it here!
  • Tough Questions. Maybe you have an answer!
  • When you're done listening to the podcast,
    check out these great sites.

Who We Are

We are the EMCrit Project, a team of independent medical bloggers and podcasters joined together by our common love of cutting-edge care, iconoclastic ramblings, and FOAM.

Like Us on Facebook

Like Us on Facebook

Subscribe by Email

EMCrit is a trademark of Metasin LLC. Copyright 2009-. This site represents our opinions only. See our full disclaimer, our privacy policy, and here for credits and attribution.

wpDiscuz
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.